Hizentra is the most prescribed self-infused subcutaneous immune globulin (SCIg) treatment and the first and only SCIg treatment approved for CIDP, allowing CIDP patients the flexibility to ...

Hizentra ®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat: Primary immune deficiency (PI) in patients 2 years and older ...

Hizentra is the most prescribed self-infused subcutaneous immune globulin (SCIg) treatment for PI in the U.S. and the first and only SCIg treatment approved for CIDP. The 50mL prefilled syringe will ...

Isra Levy, CBS’s vice-president of medical affairs and innovation, stressed that there is only a potential, not an actual, shortage of subcutaneous immune globulin, or SCIg, which patients ...

XEMBIFY® (immune globulin subcutaneous, human–klhw) is a 20% immune globulin solution for subcutaneous injection indicated for treatment of primary humoral immunodeficiency (PI) in patients 2 ...

What are the different types of immune globulin products available in the market? A. The main types of immune globulin products include intravenous immune globulin (IVIG), subcutaneous immune globulin ...

OSAKA, Japan & CAMBRIDGE, Mass. — Takeda ( TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin Subcutaneous ...

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous ...

XEMBIFY® (immune globulin subcutaneous, human-klhw) is a 20% immune globulin solution for subcutaneous injection indicated for treatment of primary humoral immunodeficiency (PI) in patients 2 ...